Hypofractionated image-guided radiation therapy (3Gy/fraction) in patients affected by inoperable advancedstage non-small cell lung cancer after long-term follow-up

Anticancer Research

Volumn 35, Issue 10, 2015, Pages 5693-5700

  Agolli, Linda ^a   Valeriani, Maurizio ^a   Bracci, Stefano ^a   Nicosia, Luca ^a   De Sanctis, Vitaliana ^a   Maurizi Enrici, Riccardo ^a   Osti, Mattia Falchetto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Advanced stage; Hypofractionated radiotherapy; Image guidance; Non small cell lung cancer; Unresectable

Indexed keywords

DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER STAGING; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; IMAGE GUIDED RADIOTHERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION PNEUMONIA; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RADIATION DOSE FRACTIONATION; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, IMAGE-GUIDED; SURVIVAL RATE;

EID: 84942778792     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gompelmann D, Eberhardt R and Herth FJ: Advanced malignant lung disease: what the specialist can offer. Respiration 82: 111-123, 2011.
2. Jassem J: The role of radiotherapy in lung cancer: where is the evidence? Radiother Oncol 83: 203-213, 2007.
3. Ramaekers BL, Joore MA, Lueza B, Bonastre J, Mauguen A, Pignon JP, Le Pechoux C, De Ruysscher DK; MAR-LC Collaborative group, Grutters JP: Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients. J Thorac Oncol 8: 1295-1307, 2013.
4. Schwarzenberger P, Fariss A, Linares L, Nedzi L and Salazar OM: Dose escalation of once weekly vinorelbine concurrent with weekly split dose hypofractionated chest radiation for palliation of advanced non-small cell lung cancer: a phase I/II study. Am J Med Sci 341: 454-459, 2011.
5. Pemberton LS, Din OS, Fisher PM and Hatton MQ: Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-center retrospective study of outcome. Clin Oncol 21: 161-167, 2009.
6. Matsuura K, Kimura T, Kashiwado K, Fujita K, Akagi Y, Yuki S, Wadasaki K, Monzen Y, Ito A, Kagemoto M, Mori M, Ito K and Nagata Y: Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/ paclitaxel in the treatment of locally advanced nonsmall-cell lung cancer. Int J Clin Oncol 14: 408-415, 2009.
7. Fowler JF and Chappell R: Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 46: 516-517, 2000.
8. Withers HR, Taylor JMG and Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27: 131-146, 1998.
9. Patridge M, Ramos M, Sardaro A and Brada M: Dose escalation for non-small cell lung cancer: analysis and modelling of published literature. Radiother Oncol 99: 6-11, 2011.
10. Van Oorschot B, Assenbrunner B, Schuler M, Backmann G and Flentje M: Survival and prognostic factors after moderately hypofractionated palliative thoracic radiotherapy for non-small cell lung cancer. Strahlenther Onkol 190: 270-275, 2014.
11. Rodrigues G, Macbeth F, Burmeister B, Kelly KL, Bezjak A, Langer C, Hanh C, Vichare A and Movsas B: International practice survey on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. Clin Lung Cancer 13: 225-235, 2012.
12. Gironés R, Torregrosa D, Gómez-Codina J, Maestu I, Tenias JM and Rosell R: Prognostic impact of comorbidity in elderly lung cancer patients: use and comparison of two scores. Lung Cancer 72: 108-113, 2011.
13. Liu YE, Lin Q, Meng FJ, Chen XJ, Ren XC, Cao B, Wang N, Zong J, Peng Y, Ku YJ and Chen Y: High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study. Radiat Oncol 8: 198, 2013.
14. Zhu ZF, Fan M, Wu KL, Zhao KL, Yang HJ, Chen GY, Jiang GL, Wang LJ, Zhao S and Fu XL: A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. Radiother Oncol 98: 304-308, 2011.
15. Osti MF, Agolli L, Valeriani M, Falco T, Bracci S, De Sanctis V and Maurizi Enrici R: Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 85: 157-163, 2013.
16. Chen WV, Ruiz BA, Hsieh MC, Wu XC, Ries LA and Lewis DR: Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer 120: 3781-92, 2014.
17. Fowler JF: 21 years of biologically effective dose. Br J Radiol 83: 554-568, 2010.
18. National Cancer Institute common terminology Criteria for adverse effects (version 4.0).
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubistein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guidelines (version1.1). Eur J Cancer 45: 228-247, 2009.
20. Kaster TS, Yaremko B, Palma DA and Rodrigues GB: Radicalintent hypofractionated radiotherapy for locally advanced nonsmall-cell lung cancer: a systematic review of the literature. Clin Lung Cancer 16: 71-79, 2015.
21. Bradley JD, Paulus R, Komaki R, Masters D, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi K, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr. and Choy H: Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16: 187-199, 2015.
22. Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, Behrendt K, Koch R, Bishop JF, Dische S, Arriagada R, De Ruysscher D and Pignon JP: Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data metaanalysis. J Clin Oncol 30: 2788-2797, 2012.
23. Din OS, Harden SV, Hudson E, Mohammed N, Pemberton LS, Lester JF, Biswas D, Magee L, Tufail A, Carruthers R, Sheikh G, Gilligan D and Hatton MQ: Accelerated hypo-fractionated radiotherapy for non-small cell lung cancer: results from 4 UK centres. Radiother Oncol 109: 8-12, 2013.
24. Kepka L, Tyc-Szczeepaniak D and Bujko K: Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer. J Thorac Oncol 4: 853-860, 2009.
25. Tsoutsou PG, Froudarakis ME, Bouros D and Koukourakis MI: Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicine for locally advanced non-small cell lung cancer (NSCLC). Anticancer Res 28: 1349-1354, 2008.
26. Donato V, Arcangeli S, Monaco A, Caruso C, Cianciulli M, Boboc G, Chiostrini C, Rauco R and Pressello MC: Moderately escalated hypofractionated (Chemo) radiotherapy delivered with helical intensity-modulated technique in stage III unresectable non-small cell lung cancer. Front Oncol 3: 286, 2013.
27. Bearz A, Minatel E, Rumeileh IA, Borsatti E, Talamini R, Franchin G, Gobitti C, Del Conte A, Trov M and Baresic T: Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel doseescalation study, with hypofractionated radiation regimen. BMC Cancer 13: 513, 2013.
28. Amini A, Lin SH, Wei C, Allen P, Cox JD and Komaki R: Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol 7: 33, 2012.
29. Kerner GS, van Dullemen LF, Wiegman EM, Widder J, Blokzijl E, Driever EM, van Putten JW, Liesker JJ, Renkema TE, Pieterman RM, Mertens MJ, Hiltermann TJ and Groen HJ: Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer. Radiat Oncol 9: 190, 2014.
30. Maguire J, Khan I, McMenemin R, O'Rourke N, McNee S, Kelly V, Peedell C and Snee M: SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status. Eur J Cancer 50: 2939-2949, 2014.
31. Kim JO, Chu KP, Fairchild A, Ghosh S, Butts S, Chu Q, Gabos Z, Joy AA, Nijjar T, Robinson DM, Sangha R, Scrimger R, Smylie M, Yee D and Roa WH: Dose-escalated hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy for inoperable or unresectable non-small cell lung cancer. Am J Clin Oncol Oct 20, 2014.
32. Zhu ZF, Ma HL, Fan M, Bao Y, Zhuang TT, Chan M, Jiang GL and Fu XL: Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer. Technol Cancer Res Treat 13: 269-275, 2014.
33. Cannon DM, Mehta MP, Adkison JB, Khuntia D, Treynor AM, Tomé WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM and Cannon GM: Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer.J Clin Oncol 31: 4343-4348, 2013.
34. Bral S, Duchateau M, Versmessen H, Engels B, Tournei K, Vinh-Hung V, De Ridder M, Schallier D and Storme G: Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable stage III non-small cell lung cancer using helical tomotherapy. Int J Radiat Oncol Biol Phys 77: 1352-1359, 2010.